Diagrammatic Illustration of Transaction

CCBC

Convertible Note 1

KKR

Convertible Note 2

Golden Meditech

Cordlife will buy 50% of Convertible Note 2 for approximately US$44.0 million from Golden Meditech

Magnum will buy 50% of Convertible Note 2 for approximately US$44.0 million from Golden Meditech

Cordlife

Magnum

- Cordlife will lend Magnum up to US$46.5 million for the purposes of financing Magnum’s portion of the convertible note and related costs
- Interest @ 7% per annum

Convertible note in the principal amount of US$65.0 million issued by CCBC in April 2012

Convertible note in the principal amount of US$50.0 million issued by CCBC in October 2012
Key Parties’ Interests in CCBC Prior To And Post-transaction

<table>
<thead>
<tr>
<th></th>
<th>Latest Publicly Available Information</th>
<th>Partial Dilution (if only Cordlife and Magnum exercise conversion option)</th>
<th>Full Dilution (If KKR, Cordlife and Magnum all exercise conversion option)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golden Meditech</td>
<td>42.03%</td>
<td>33.86%</td>
<td>27.03%</td>
</tr>
<tr>
<td>KKR</td>
<td>-</td>
<td>-</td>
<td>20.17%</td>
</tr>
<tr>
<td>Cordlife</td>
<td>10.02%</td>
<td>17.79%</td>
<td>14.20%</td>
</tr>
<tr>
<td>Magnum</td>
<td>-</td>
<td>9.72%</td>
<td>7.76%</td>
</tr>
</tbody>
</table>

* All figures are rounded to the nearest 2 decimal places
Key Parties’ Interests in CCBC if Cordlife did not participate in the acquisition of Convertible Note

<table>
<thead>
<tr>
<th></th>
<th>Latest Publicly Available Information</th>
<th>Partial Dilution (if KKR exercises conversion option)</th>
<th>Full Dilution (If KKR and Magnum exercise conversion option)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golden Meditech</td>
<td>42.03%</td>
<td>31.99%</td>
<td>27.03%</td>
</tr>
<tr>
<td>KKR</td>
<td>-</td>
<td>23.88%</td>
<td>20.17%</td>
</tr>
<tr>
<td>Cordlife</td>
<td>10.02%</td>
<td>7.63%</td>
<td>6.44%</td>
</tr>
<tr>
<td>Magnum</td>
<td>-</td>
<td>-</td>
<td>15.52%</td>
</tr>
</tbody>
</table>

* All figures are rounded to the nearest 2 decimal places
Salient Terms of the CGL Note and Facility

PROPOSED ACQUISITION OF 7% SENIOR CONVERTIBLE NOTE ("CGL Note") DUE 2017 ISSUED BY CHINA CORD BLOOD CORPORATION ("CCBC")

- 7% coupon on US$2.838
- Expiry date of convertible notes
  - KKR (27 April 2017);
  - Cordlife/Magnum (3 October 2017)
- CGL Note converts into 8,809,020 fully paid CCBC shares, at a conversion price of approximately US$5.00, based on the purchase price of approximately US$44 million
- Assuming redemption of CGL Note upon maturity and taking into account only receipt of 7% coupon payment, salvage value at 12% IRR is equivalent to approximately US$3.80 per share
- Participating shareholder in excess cash dividend, if CCBC ordinary shareholders receive cash dividend in excess of 7% of US$2.838 or approximately US$0.1984 per share
- Penalty on default: Principal amount of CGL Note may be redeemed at a price which, inclusive of interest, would yield a 22.5% IRR on outstanding principal to date of payment

PROPOSED US$46,500,000 FACILITY TO BE GRANTED TO MAGNUM OPUS INTERNATIONAL HOLDINGS LIMITED ("MAGNUM")

- Upfront non-refundable fee of approximately US$1.45 million paid to Cordlife
- Interest is payable at 7% per annum semi-annually for the first 3 years; and at the higher of 4.6% over the Swap Offer Rate or 7% per annum, in the 4th and 5th years
- Assuming full drawdown, Cordlife’s interest income shall be US$3,255,000 in each of the first 3 years, US$2,848,125 in the 4th year and US$1,220,625 in the 5th year
- Facility to be repaid in 4 equal instalments, on the dates falling 42, 48, 54 & 60 months after the 1st drawdown date
Inorganic growth opportunity: China

Leveraging platform in China for expansion and growth

Key China milestones

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cordlife acquires 10.0% of CCBC for approximately US$20.8 million</td>
<td>12 Nov 2012</td>
</tr>
<tr>
<td>Extends strategic alliance with CordLabs Asia for the provision of human postnatal umbilical cord lining storage services in China</td>
<td>3 March 2014</td>
</tr>
<tr>
<td>Cordlife reinforcing commitment to long term CCBC partnership via acquisition of CCBC Convertible Note</td>
<td>On-going</td>
</tr>
</tbody>
</table>

China Cord Blood Corporation (NYSE: CO US)

- China’s largest cord blood banking operator
- Owns 3 out of 7 issued licenses in PRC to operate cord blood banking. Only 1 licensed operator permitted to operate in each licensed region
- Exclusive license to provide cord blood storage services in Beijing, Guangdong and Zhejiang and approximately 24.0% stake in Shandong Cord Blood Bank
- As at 31 March 2014, CCBC has collaborative relationships with 312 major hospitals in Beijing, Guangdong and Zhejiang.

Acquisition of China Cord Blood Corporation Convertible Note

- Cordlife able to raise its interest in CCBC from 10.0% to approximately 17.8%
- Magnum (sole shareholder is Mr Yuen Kam, Chairman of CCBC, and management of CCBC) also acquired an equal amount of convertible note in dollar terms which is funded through a facility agreement between Cordlife and Magnum
- Steady source of income from recurring annual coupon payments of US$1.75 million
QUESTIONS?

cordlife – A Consumer Healthcare Company, listed on the Mainboard of SGX-ST.